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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the diagnostic accuracy of the magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography
(MRCP) for detecting the presence of bile duct stenosis.
To evaluate the ability of the MRI and MRCP to determine the site of stenosis.
To evaluate the ability of MRI and MRCP to differentiate between benign and malignant bile duct stenosis.
B A C K G R O U N D
Bile duct stenosis is an abnormal stricture that causes impairment
to the normal flow of bile on its way to the small bowel. Clini-
cally, it manifests with jaundice, which represents with staining of
the skin and sclerae by high blood levels of bilirubin (Friedman
2010). Among the causes for obstruction of the biliary system
are stones, lymphadenopathy, benign tumours, primary biliary tu-
mours, extension of other malignancies from other regions of the
gastrointestinal tract, pancreatic masses, metastases to the liver,
and cholangiocarcinoma. The treatment of bile duct stenosis de-
pends on the type of obstruction, site, and extension of disease in
question.
There are some difficulties in determining a rational strategy to
evaluate people with jaundice by imaging methods. Jaundice is a
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clinical finding, not a single disease entity. The first task of the
clinician caring for a person with jaundice is to determine if jaun-
dice is caused by bile duct obstruction. People with a high pre-test
probability of non-obstructive jaundice usually need no imaging
investigations (ACR 1996).
It is an important challenge to differentiate between benign and
malignant causes for biliary stenosis. Although the information ac-
quired from cross-sectional imaging studies may suggest the most
probable underlying cause, it is obscured in up to 50% of people
(Yoo 2014). Indeed, the final diagnosis in people with stenosis
without a demonstrable mass on an imaging investigation in cross-
sectional studies is difficult.
The imaging methods, currently used in evaluating obstruc-
tive jaundice, include abdominal ultrasonography, computed to-
mography, magnetic resonance imaging (MRI), magnetic reso-
nance cholangiopancreatography (MRCP), endoscopic retrograde
cholangiopancreatography (ERCP), and percutaneous transhep-
atic cholangiography (PTC) (Zhong 2005). These examinations
are effective to varying degrees for assessing both the aetiology and
site of obstructions.
Abdominal ultrasonography is the least invasive and cheapest
imaging technique available for evaluating obstructive jaundice.
It is a quick and easy test, suitable for initial diagnostic imaging.
Its sensitivity ranges between 55% and 95% and specificity be-
tween 71% and 96% (Yusoff 2003). Ultrasound is less effective
than computed tomography and MRCP for determining the site
and cause of biliary obstruction (Yusoff 2003).
Computed tomography is slightly more sensitive (74% to 96%)
and specific (90% to 94%) than ultrasound for detecting biliary
stenosis (ACR 1996).
MRI can demonstrate both the site and cause of stenosis. MRCP is
useful in depicting the biliary anatomy (ACR 1996). The combi-
nation of MRI and MRCP represents another non-invasive imag-
ing modality showing an excellent soft tissue contrast and having
the ability to demonstrate pathological and congenital conditions
(Yoo 2014).
ERCP is the most common invasive diagnostic biliary procedure.
Due to significant advances in cross-sectional imaging, in partic-
ular the advent of MRCP, the current role of ERCP is exclusively
therapeutic (ACR 1996).
One study evaluating tumour extension and potential resectability
of bile duct cancer concluded that the findings of MRCP com-
bined with theMRI findings are comparable with themulti detec-
tor computed tomography (MDCT) and direct cholangiography
(Park 2008).
People with suspected stenosis require an effective diagnostic test
that can differentiate between low-risk malignant disease that
could be cured with minimally invasive therapies and high-risk
malignant disease that would benefit from surgical exploration.
Thus, the diagnosis of the cause of biliary stricture has an impor-
tant role in optimising the treatment. It seems that combination
of MRI and MRCP could be used for differentiating causes of
benign and malignant biliary strictures.
Target condition being diagnosed
Bile duct stenosis - presence, site, and aetiology
(benign versus malignant stenosis)
Biliary strictures, biliary stenosis, or bile duct stenosis are synony-
mous. Stenosis is defined as a constriction or narrowing of a duct
or passage (The American Heritage Dictionary). Many diseases
could lead to a biliary stenosis.
Diseases that lead to stenosis could affect the biliary ducts in any
site of the biliary tree, from the small ducts in the periphery of the
liver to the distal portion of choledochal duct.
Choledocholithiasis andmalignant bile duct tumours are themost
common diseases that involve the biliary system, and pancreatitis
and pancreatic carcinoma are the most common disorders of the
pancreas (Reinhold 1996). All of these diseases could lead to direct
or indirect stenosis of the biliary tree.
Benign and malignant stenosis have different imaging presenta-
tions. Abrupt termination of the bile duct is a cholangiographic
sign that has a high correlation with malignancy, whereas a grad-
ually tapering duct correlates with a benign process. These fea-
tures can be visualised through cholangiographic images or with
correlation with sequential axial images. The key to achieving a
proper diagnosis of benign or malignant stenosis is to analyse the
transition zone between the stenotic and non-stenotic area. Some
radiologists recognise the need to evaluate axial T1-weighted and
T2-weighted images sequentially for complete evaluation of the
transition zone of the bile duct obstruction for extra-ductal and
intraductal findings (Baron 2002).
Index test(s)
Magnetic resonance cholangiopancreatography and
magnetic resonance imaging
The index test will be a combination of sequences of MRI using
both MRCP and MRI of the abdomen.
MRI is a non-invasive imaging technique, which uses a magnetic
field that can produce imaging of the whole body. These im-
ages have a good contrast between the different tissues. MRI per-
mits combining the benefits of cross-sectional and projection tech-
niques, without moving the person. MRI does not use radiation.
MRCP is a non-invasive test that can produce images of the bil-
iary tree. This technique is based on heavily T2-weighted pulse
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sequences. As a result, stationary fluids have a high signal intensity,
while solid organs have a low signal intensity (Reinhold 1996).
MRCP images can be obtained using a variety of pulse sequences.
HASTE (half-Fourier acquisition single-shot turbo spin-echo),
Gradient-Echo (Steady-State Free Precession Signals - SSFP), and
RARE (rapid acquisition with relaxation enhancement sequences)
are pulse sequences available for studies of biliary and pancreatic
ducts (Miyazaki 1996; Reinhold 1996; Patel 2009). Breath-hold
HASTE MRCP can be used as a non-invasive screening method
for pancreaticobiliary diseases (Miyazaki 1996). MRCP can pro-
vide diagnostic information equivalent to invasive techniques in a
large percentage of people (Barish 1995).
We will consider the index test positive for biliary stenosis if any
narrowing in the biliary tree, associated or not to biliary dilation,
is shown on the image. We will consider the index test negative
for stenosis in the cases when the diameter of the bile duct is not
reduced.
Clinical pathway
People with jaundice, leading to cholestasis, usually undergo diag-
nostic laboratory tests such as bilirubin, alkaline phosphatases, or
gamma-glutamyl transpeptidase to differentiate obstructive from
non-obstructive jaundice. People with high probability of non-
obstructive jaundice usually do not undergo imaging tests. People
with tests suggesting obstructive jaundice, usually undergo further
investigation.
With the availability of newer imaging and sampling methods,
algorithms for diagnostic evaluation and management of people
with suspected biliary obstruction evolved. ERCP is no longer rou-
tinely recommended and hence, it is not the initial test of choice.
Biliary strictures remain a diagnostic enigma and the possibility of
achieving an early and accurate diagnosis is high. While abdomi-
nal imaging helps in finding the level of obstruction and provides
a ’road map’ for further endoscopic investigations, tissue diagnosis
is usually needed to make decisions on management (Singh 2015)
(Figure 1).
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Figure 1. Clinical pathway:Proposed diagnostic approach to biliary strictures (modified from Singh
2015).EUS-FNA: endoscopic ultrasound-fine needle aspiration; ERCP: endoscopic retrograde
cholangiopancreatography; IDUS: intraductal ultrasound; MRI/MRCP: magnetic resonance imaging/magnetic
resonance cholangiopancreatography; SOC: single operator cholangioscopy; US: ultrasound. For results with
low likelihood of malignancy, close observation and follow-up are indicated.* Once malignancy is confirmed by
any modality, surgical and oncology referral should be obtained.
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Alternative test(s)
The imaging methods, currently used in evaluating obstructive
jaundice, include abdominal ultrasonography, computed tomog-
raphy,MRI, MRCP, ERCP, and PTC. These imaging methods are
effective to varying degrees for assessing presence, site, and aetiol-
ogy of stenosis. The sequence in which these tests are used is not
standardised (Mosler 2011).
In people with mild symptoms, less invasive tests (e.g., transab-
dominal ultrasound, computed tomography, MRI, MRCP, or en-
doscopic ultrasound) are often used to establish diagnosis and
guide further management. The recent literature has emphasised
that more invasive modalities should be reserved for people with
an indication for therapeutic intervention (Mosler 2011).
Rationale
We consider that the combination of themagnetic resonance tech-
niques - MRCP and MRI - may improve the pathway of diag-
nosis of diseases that cause stenosis of the biliary tree (Haliloglu
2009). The combination of MRCP and MRI allows an accurate
imaging of the site, extension, and cause of stenosis (Catalano
1998; Hänninen 2002; Hänninen 2005). These magnetic reso-
nance techniques could be used to direct properly people to ERCP
and to plan a certain therapy. Some study authors have already
demonstrated that the use of MRCP plus MRI significantly im-
proves the diagnostic accuracy of MRI examinations for diseases
of the biliary system (Kim 2000; Kim 2006; Kim 2007).
In the cases when an ultrasound investigation result is negative,
based on a high pre-test probability of biliary obstruction, further
tests are necessary for the management of people with cholestasis
(ACR1996).Many factors could be responsible for a false-negative
ultrasound result; for example, the absence of biliary dilation in the
presence of obstruction or stenosis, the expertise of the examiner,
or the inability to visualise the extrahepatic biliary tree (Baron
2002).
Furthermore, as previously stated, there is no standardisation of
the imaging method for the diagnostic evaluation of people with
biliary stenosis (Mosler 2011).
O B J E C T I V E S
To determine the diagnostic accuracy of the magnetic resonance
imaging (MRI) and magnetic resonance cholangiopancreatogra-
phy (MRCP) for detecting the presence of bile duct stenosis.
Secondary objectives
To evaluate the ability of the MRI and MRCP to determine the
site of stenosis.
To evaluate the ability ofMRI andMRCP to differentiate between
benign and malignant bile duct stenosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include prospective and retrospective studies assessing the
diagnostic accuracy of MRCP plus MRI in consecutive series of
people with suspected bile duct stenosis. We will include studies
irrespective of publication status or language. We will not include
participant/control design studies. We will exclude studies using
MRCP alone as we intend to verify the accuracy of the combina-
tion of MRCP plus MRI.
Participants
Adults of either sex with suspicion of biliary stenosis, symptomatic
or asymptomatic, with laboratory changes, that is, changes in
serum levels of bilirubin, alkaline phosphatase, and gamma glu-
tamyl transferase above the normal range. People with symptoms
could present with cholestasis, defined by jaundice, choluria, and
acholic stools. They could also present with upper right abdominal
pain, fever, and weight loss. We will also consider inclusion of data
from people with or without symptoms, if they were investigated
using abdominal ultrasonography before the index test.
Index tests
The index test will be the combination of MRCP plus MRI tech-
niques.
Target conditions
Target conditions will be: presence, site, and nature (benign or
malignant) of stenosis. We plan to include studies on any of these
three target conditions as well as studies on the presence, location,
or cause of stenosis.
We will define bile duct stenosis as any degree of narrowing of the
diameter of the biliary ducts observed by the use of the reference
standard.
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We will dichotomise the site of the biliary stenosis in two cate-
gories: intrahepatic and extrahepatic. We will define intrahepatic
stenosis as narrowing in the biliary tree inside the liver, including
the common hepatic duct. We will define extrahepatic stenosis as
narrowing at any portion of the choledochal duct.
The nature of bile duct stenosis will be categorised as benign and
malignant. A malignant bile duct stenosis is produced by a pri-
mary biliary cancer or extension of other malignancies from dif-
ferent regions of the body (e.g., cholangiocarcinoma, liver metas-
tasis, pancreatic adenocarcinoma) and a benign biliary stenosis is
produced by causes different from malignant neoplasm, such as
inflammatory process, papillary changes, and benign neoplasms.
To differentiate the nature of stenosis with the index test, we will
analyse the transition zone between the stenotic and non-stenotic
area. A malignant stenosis is represented by an abrupt termina-
tion between the stenotic and non-stenotic duct. Benign stenosis
is represented by a gradually tapering duct.
Reference standards
The reference standard is ERCP alone or in a combination with
any of the following diagnostic tests: intraoperative cholangiopan-
creatography, PTC, endoscopic ultrasonography, surgical explo-
ration, or histopathology. We will also consider accepting as a ref-
erence standard a follow-up of participants with a negative index
test for a period of no less than one month.
ERCP alone, or ERCP in combination with PTC and endoscopic
ultrasonography tests will be the reference standard(s) to define
the presence and site of stenosis.
The combination of clinical follow-up, surgical exploration, and
histopathology will be the reference standard to differentiate be-
tween benign and malignant causes of stenosis.
Search methods for identification of studies
Electronic searches
We will search The Cochrane Hepato-Biliary Controlled Trials
Register and The Cochrane Hepato-Biliary Diagnostic Test of Ac-
curacy Studies Register, The Cochrane Library, MEDLINE, EM-
BASE, Science Citation Index, and LILACS (Royle 2003). We
will apply no language or document type restrictions.
We list the preliminary search strategies with the expected time
spans of the searches in Appendix 1.
Searching other resources
We will also screen reference list of the included studies.
Data collection and analysis
Two review authors (AJCN and SASL) will review the abstracts of
the retrieved publications and select those that are likely to meet
the inclusion criteria. Four review authors (AJCN, SASL, CR,
and MPG) will independently collect data for analyses. If there
are disagreements, the authors will discuss these until they reach
consensus.
Selection of studies
A study publication has to be an assessment of the accuracy of the
index test in people with suspected biliary stenosis. Four review
authors (AJCN, SASL, CR, and MPG) will independently review
the publications for further data extraction.
Data extraction and management
Two review authors (AJCN, SASL)will independently extract data
fromall included studies using a data collection form.Three review
authors (AJCN, SASL, andGD) will deal critically with the results
and will resolve any disagreements by checking the publication
study data.
Data extraction will include study design, year of publication, size
of sample, data for 2 x 2 tables (true positives, false positives, true
negatives, false negatives) or data for 3 x 2 tables, withdrawals and
reasons, reference standard, diseases, strength of magnetic field,
and assessment of all the items ofQualityAssessment ofDiagnostic
Accuracy Studies (QUADAS-2) in terms of bias risk of the studies
(Whiting 2011).
We also intend to extract data for people with or without abdom-
inal ultrasonography investigation before the index test. Ultra-
sound imaging results could have an effect on diagnostic pre-test
probability. Participants with ultrasound-positive results could af-
fect the accuracy of the index test and the reference standard. We
will consider these results as a source of heterogeneity.
We will extract data for 2 x 2 tables to evaluate the ability of the
index test to differentiate the site of bile duct stenosis as intrahep-
atic or extrahepatic.
In the case of indeterminate index test results and if the primary
studies allow, we will extract data for a 3 x 2 table (true positives,
false positives, true negatives, false negatives, non-evaluable re-
sults). The ’classic’ 2 x 2 table does not hold enough information to
show the true range of possible results. By simply excluding non-
evaluable results, the values of sensitivity and specificity become
overestimated (Schuetz 2012).
Assessment of methodological quality
We will assess the selected studies using QUADAS-2, as recom-
mended by the Cochrane Handbook for Systematic Reviews of Di-
agnostic Test Accuracy (still in draft) (DTA Handbook 2009).
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Three review authors (AJCN, SASL, and GD) will independently
assess the quality of the studies, and resolve any disagreements by
consensus.
Appendix 2 presents a detailed definition of criteria for signalling
questions, risk of bias, and concerns about applicability of the four
domains of QUADAS-2.
We will consider studies at low risk of bias only if the studies
are classified as low risk of bias considering all the QUADAS-2
domains.
Statistical analysis and data synthesis
We will create a 2 x 2 table of the diagnostic accuracy of MRI
plus MRCP for diagnosing the presence, or the site, or the aetiol-
ogy (benign versus malignant) of biliary stenosis. We will report
sensitivity, specificity, and positive and negative likelihood ratios
(LR+ and LR-) with their 95% confidence intervals (CI) for each
primary study. We will perform a graphical descriptive analysis of
the included studies with forest plots (of sensitivity and specificity)
and with graphical representation of the studies in the receiver
operating characteristic (ROC) space (plot of sensitivity versus 1 -
specificity). We will fit the bivariate model fitted (Reitsma 2005),
and use the results to calculate the pooled estimates of sensitivity
and specificity (mean operating point). We will obtain summary
estimates of LRs frommodel-derived sensitivity and specificity es-
timates.
If primary studies present non-evaluable results about the index
test, we will create a 3 x 2 table of diagnostic accuracy of index test
for bile duct stenosis.Wewill then adopt the intention-to-diagnose
approach to build 2 x 2 tables for meta-analyses. According to
this approach, we will include non-evaluable results either in the
false-negative or false-positive cell of the 2 x 2 table, as appropriate
(Schuetz 2012).
If possible, we will add some relevant co-variates to the bivariate
model to investigate the effect of the pre-defined sources of hetero-
geneity on the accuracy estimates (Investigations of heterogeneity).
We will perform statistical analyses with statistical software SAS,
release 9.2.
Investigations of heterogeneity
We will investigate heterogeneity in a descriptive way (forest plots
for various subgroups of studies), as well as in a more formal way,
by adding co-variates to the bivariate model.
We consider the following as potential sources of heterogeneity.
• MRCP technological differences in the magnetic strength
field (0.5 Tesla (T) versus 1.0 T versus 1.5 T).
• Type of reference standard. We will define three categories:
◦ direct cholangiographies: represented by ERCP,
intraoperative cholangiopancreatography, PTC;
◦ surgical types: represented by surgical exploration,
histopathological findings, and clinical; and
◦ other imaging tests: represented by clinical follow-up
and endoscopic ultrasonography.
• Clinical context (studies with people not undergoing
surgery versus studies with people undergoing surgery).
• Participants submitted to other imaging tests before the
index test or reference standard, including people with positive
transabdominal ultrasound.
• Type of disease that led to stenosis.
Sensitivity analyses
We will undertake sensitivity analyses to explore the effect on
overall results of studies with high risk of bias, by including only
the studies classified at low risk of bias in the analyses.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Time span Search strategy
CochraneHepato-BiliaryControlledTrials
Register
Date will be given at review stage. ((((Bile AND (duct OR tract)) OR biliary OR
pancreatic* OR biliopancreatic*) AND (tumor*
OR lesion* OR injur* OR strictur* OR disease*
OR disorder* OR obstruction* OR stenos*)) OR
(Chronic pancreatitis OR cholangitis OR focal
wall thickening OR choledochal varices OR (por-
tal AND (biliopathy OR cavernoma)) OR obstruc-
tive jaundice OR bile leakage OR retained stones
OR (bile duct AND (intrahepatic OR aberrant))
OR intraductal masses OR duct lumen)) AND (
((NMR OR MR OR protonspin OR magnetiza-
tion OR MRI OR chemical shift) AND (imag-
ing OR tomography OR scan)) OR (magnetic res-
onance cholangiopancreatograph* OR zeugmato-
graph* OR functional MRI))
Cochrane Hepato-Biliary Diagnostic Test
of Accuracy Studies Register
Date will be given at review stage. ((((Bile AND (duct OR tract)) OR biliary OR
pancreatic* OR biliopancreatic*) AND (tumor*
OR lesion* OR injur* OR strictur* OR disease*
OR disorder* OR obstruction* OR stenos*)) OR
(Chronic pancreatitis OR cholangitis OR focal
wall thickening OR choledochal varices OR (por-
tal AND (biliopathy OR cavernoma)) OR obstruc-
tive jaundice OR bile leakage OR retained stones
OR (bile duct AND (intrahepatic OR aberrant))
OR intraductal masses OR duct lumen)) AND (
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((NMR OR MR OR protonspin OR magnetiza-
tion OR MRI OR chemical shift) AND (imag-
ing OR tomography OR scan)) OR (magnetic res-
onance cholangiopancreatograph* OR zeugmato-
graph* OR functional MRI))
The Cochrane Library Latest issue. #1 MeSH descriptor: [Bile Ducts] explode all trees
#2 MeSH descriptor: [Biliary Tract Diseases] ex-
plode all trees
#3 MeSH descriptor: [Adenoma, Bile Duct] ex-
plode all trees
#4 MeSH descriptor: [Choledochal Cyst] explode
all trees
#5 MeSH descriptor: [Pancreatic Neoplasms] ex-
plode all trees
#6MeSHdescriptor: [Pancreatitis] explode all trees
#7 MeSH descriptor: [Cholangiocarcinoma] ex-
plode all trees
#8 MeSH descriptor: [Carcinoma, Hepatocellular]
explode all trees
#9 MeSH descriptor: [Jaundice, Obstructive] ex-
plode all trees
#10MeSH descriptor: [Liver Cirrhosis] explode all
trees
#11 ((((Bile and (duct or tract)) or biliary or pan-
creatic* or biliopancreatic*) and (tumor* or lesion*
or injur* or strictur* or disease* or disorder* or ob-
struction* or stenos*)) or (Chronic pancreatitis or
cholangitis or focal wall thickening or choledochal
varices or (portal and (biliopathy or cavernoma))
or obstructive jaundice or bile leakage or retained
stones or (bile duct and (intrahepatic or aberrant))
or intraductal masses or duct lumen))
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
or #9 or #10 or #11
#13MeSHdescriptor: [Magnetic Resonance Imag-
ing] explode all trees
#14 (((NMR or MR or protonspin or magnetiza-
tion or MRI or chemical shift) and (imaging or to-
mography or scan)) or (magnetic resonance cholan-
giopancreatograph* or zeugmatograph* or func-
tional MRI))
#15 #13 OR #14
#16 #12 AND #15
MEDLINE 1990 to the date of search. # 1 ’nuclear magnetic resonance imaging’: ab,ti
# 2 ’nuclear magnetic resonance imaging’/exp
# 3 ’magnetization transfer imaging’:ab,ti
# 4 mrcp: ab,ti OR mri: ab,ti OR nmr: ab,ti AND
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imaging: ab,ti OR fmri: ab,ti
# 5 mrcp:ab,ti OR mri:ab,ti OR ’nmr imaging’:ab,
ti OR fmri:ab,ti
# 6 cholangiopancreatograph*: ab,ti
#7 #1 OR #2 OR #3 OR #4 OR #5
#8 #6 OR #7
#9 ’digestive system diseases’/exp
#10 ’biliary tract’: ab,ti
#11 ’bile duct’:ab,ti
#12 ’biliary duct’:ab,ti
#13 ’jaundice’:ab,ti
#14 ’stenosi’:ab,ti OR ’strictur’:ab,ti OR ’narrow’:
ab,ti OR ’explore’:ab,ti OR ’exploration’:ab,ti
#15 ’biliary stricture’:ab,ti
#16 #10 OR #11 OR #12
#17 #14 AND #16
#18 #13 OR #15 OR #17
#19 #9 OR #18
#20 #8 AND #19
EMBASE 1990 to the date of search. # 1 ’nuclear magnetic resonance imaging’: ab,ti
# 2 ’nuclear magnetic resonance imaging’/exp
# 3 ’magnetization transfer imaging’:ab,ti
# 4 mrcp: ab,ti OR mri: ab,ti OR nmr: ab,ti AND
imaging: ab,ti OR fmri: ab,ti
# 5 mrcp:ab,ti OR mri:ab,ti OR ’nmr imaging’:ab,
ti OR fmri:ab,ti
# 6 cholangiopancreatograph*: ab,ti
#7 #1 OR #2 OR #3 OR #4 OR #5
#8 #6 OR #7
#9 ’digestive system diseases’/exp
#10 ’biliary tract’: ab,ti
#11 ’bile duct’:ab,ti
#12 ’biliary duct’:ab,ti
#13 ’jaundice’:ab,ti
#14 ’stenosi’:ab,ti OR ’strictur’:ab,ti OR ’narrow’:
ab,ti OR ’explore’:ab,ti OR ’exploration’:ab,ti
#15 ’biliary stricture’:ab,ti
#16 #10 OR #11 OR #12
#17 #14 AND #16
#18 #13 OR #15 OR #17
#19 #9 OR #18
#20 #8 AND #19
Science Citation Index Expanded 1900 to the date of search. #1TS=((((Bile and (duct or tract)) or biliary or pan-
creatic* or biliopancreatic*) and (tumor* or lesion*
or injur* or strictur* or disease* or disorder* or ob-
struction* or stenos*)) or (Chronic pancreatitis or
cholangitis or focal wall thickening or choledochal
varices or (portal and (biliopathy or cavernoma))
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or obstructive jaundice or bile leakage or retained
stones or (bile duct and (intrahepatic or aberrant))
or intraductal masses or duct lumen))
#2 TS=(((NMR or MR or protonspin or magne-
tization or MRI or chemical shift) and (imaging
or tomography or scan)) or (magnetic resonance
cholangiopancreatograph* or zeugmatograph* or
functional MRI))
#3 #1 AND #2
LILACS 1990 to the date of search. #1 (MH VALOR PREDITIVO DOS TESTES
OR tw VALOR PREDITIVO DOS TESTES OR
MH SENSIBILIDADE E ESPECIFICIDADE
OR tw SENSIBILIDADE E ESPECIFICIDADE
OR MH DIAGNOSTICO OR tw DIAGNOS-
TICO) OR ((tw sensitiv$ OR tw sensibili$ OR tw
specific$OR tw especific$) AND tw diagnos$) OR
((tw predictiv$ OR tw preditiv$) AND (tw test$
OR tw prueba$))
#2 mh ductos biliares OR mh bile ducts OR mh
conductos biliares OR tw canais biliares OR tw
ductos biliferos OR tw via biliar OR tw vias biliares
OR ex a03.159.183$ OR mh bile ducts, intrahep-
atic OR mh conductos biliares intrahepaticos OR
tw canais biliares intra-hepaticos OR tw via biliar
intra-hepatica OR tw vias biliares intra-hepaticas
ORexA03.620.150$ORmHbile ducts, extrahep-
atic ORmH conductos biliares extrahepaticos OR
mH ductos biliares extra-hepaticos OR tw sistema
biliar extra-hepaticoOR twvia biliar extra-hepatico
OR tw vias biliares extra-hepaticos OR mH bile
ducts diseases OR mH enfermedades de los con-
ductos biliares ORmH doenças dos ductos biliares
OR tw doenças das vias biliares OR ex C06.130.
120$ OR mH neoplasias dos ductos biliares OR
mH bile duct neoplams OR mH neoplasias de los
conductos biliares OR tw câncer dos ductos biliares
OR tw câncer do ducto$ biliar$ OR tw neoplasias
do ducto$ biliar$ OR tw tumores das vias OR
ex C04.588.274.120.250$ OR ex C06.130.120.
120$ORexC06.130.320.120$ORC06.301.120.
250$ ORmH choledocholithiasis ORmH coledo-
colitiasis OR mH coledocolitiase OR tw coletiase
do ducto OR tw biliar comumOR tw colelitiase do
colédoco OR ex C06.130.120.250.174$C06.130.
409.267$ ORmH gallstones ORmH cálculos bil-
iares OR tw cálculos nas vias biliares OR tw cal-
culo do trato biliar OR tw pedras no trato biliar
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OR tw cálculos na vesícula biliar OR tw pedras
na vesícula biliar OR ex C06.130.409.633$ OR
ex C06.130.564.332.500$ OR ex C23.300.175.
525$ OR mH pancreatic neoplasms OR mH neo-
plasias pancreáticas OR tw câncer$ do pâncrea$
OR tw câncer pancreatic$OR tw tumor$ pancrea$
OR ex C04.588.274.761$ OR ex C04.588.322.
421$ OR ex C06.301.761$ OR ex C06.689.667$
OR C19.344.421$
#3 MH Cholangiopancreatography, magnetic res-
onance OR mH pancreatocolangiografia por reso-
nancia magnética ORmH colangiopancreatografia
por ressonância magnética OR tw MRCP OR tw
colangiopancreatograf$ OR ex E01.370.350.500.
100$ OR E01.370.350.825.500.100$ OR E01.
370.372.207$ OR mH cholangiography OR mH
colangiografia OR mH colangiografia OR ex E01.
370.350.700.715.200$ OR E01.370.372.200$
#4 MH magnetic resonance imaging OR mH im-
agen por resonancia magnética OR mH imagem
por ressonância magnética OR tw imagem por res-
sonância magnética OR tw imageamento por res-
sonância magnética OR tw imagem por chemical
shift OR tw tomografia por RM OR tw tomo-
grafia por RMN OR tw tomografia por spin do
próton OR tw varreduras por irm OR tw imagem
contrastada por transferência de magnetização OR
tw irmf OR tw image$ por ressonanc$ OR tw
magnetic$ funciona$ OR tw irm funcional OR
ex E01.370.350.500$ OR E01.370.350.825$ OR
SP4.001.002.015.044.010.006$
#1 AND 2 AND 3 AND 4
Appendix 2. QUADAS-2 criteria definition for signalling questions
Domain Participant selection Index test Reference standard Flow and timing
Signalling questions
and criteria
1. Was a consecutive or
random sample of par-
ticipants enrolled?
Answer:
Yes - if the study reported
on a consecutive or a ran-
dom selection of partici-
pants
No - if the study reported
1. Were the combi-
nation of MRCP and
MRI results interpreted
without knowledge of
the results of the refer-
ence standard?
Answer:
Yes - if the study re-
ported that the results
1. Was the pool of ref-
erence standards used
correctly in terms of the
target conditions, i.e.,
ERCP, PTC, and en-
doscopic ultrasonogra-
phy for presence and
site of stenosis; surgery,
histopathology,
1. Was there an appro-
priate interval between
the index test and the
reference standard?
Answer:
Yes - if the interval be-
tween the index test and
the reference standard
was hours to 7 days,
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on another form of selec-
tion of participants
Unclear - if the study
did not report on how
the participants were en-
rolled
2. Did the study avoid
inappropriate
exclusions?
Answer:
Yes - if the study reported
all exclusions and causes.
No - if the study re-
ported exclusions be-
cause of “non-diagnostic
imaging by artefacts”
Unclear - if the study did
not report causes of ex-
clusions.
3. Were the partici-
pants with the target
condition submitted to
other imaging tests be-
fore the index test and
reference standard?
Answer:
Yes - if other imaging
tests were used (ultra-
sonography, computed
tomography)
No - no other imaging
tests were used.
Unclear - if the study
does not report the use of
other imaging tests
of the combination of
MRCP and MRI were
interpreted without the
knowledge of the results
of the reference standard
No - if the study reported
that the results of the
combination of MRCP
and MRI were inter-
preted with the results of
the reference standard
Unclear - if the study did
not report information
about blinding of the re-
sults of the combination
of MRCP and MRI and
reference standard
2. If a threshold was
used, was it pre-speci-
fied?
Answer:
Yes - if the study re-
ported a value to con-
sider a bile duct dilation
beyond stenosis
No - if the study re-
ported bile duct dilation
without a pre-specified
threshold
Unclear - if the study re-
ported stenosis and the
presence of bile duct di-
latation, but the study
was not clear if a thresh-
old was used
and clinical follow-up
for the nature of steno-
sis (benign and malig-
nant)?
Answer:
Yes - if studies used
ERCP, PTC, and en-
doscopic ultrasonogra-
phy for presence and
site of stenosis, surgery,
histopathology, and clin-
ical follow-up for the na-
ture of stenosis
No - if studies did not
use the pool of reference
standards for correct tar-
get conditions
Unclear - if studies did
not specify how the pool
of reference standards
was used to define the
target condition
2. Were the reference
stan-
dard results interpreted
without the knowledge
of the results of the in-
dex test?
Answer:
Yes - if the study reported
that the results of the
reference standard were
interpreted without the
knowledge of the results
of the index test
No - if the study reported
that the results of the ref-
erence standard were in-
terpreted with the results
of the test index
Unclear - if the study
did not report informa-
tion about blinding of
the results of the refer-
ence standard and the in-
dex test
when the reference stan-
dard was not the clini-
cal follow-up, and no less
than 1 month when the
reference standard was
the clinical follow-up
No - if the interval was
longer than 7 days when
the reference standard
was not the clinical fol-
low-up, and less than 30
days, when the reference
standard was the follow-
up
Unclear - if the study did
not report the interval
between the index test
and the reference stan-
dard
2. Did all study partic-
ipants receive a refer-
ence standard?
Answer:
Yes - if all participants re-
ceived a reference stan-
dard.
No - if there were with-
drawals because some
participants did not re-
ceive the reference stan-
dard
Unclear - if the study did
not report if all partici-
pants received the refer-
ence standard or not
3. Did all participants
receive the same refer-
ence standard?
Answer:
Yes - if the study had
only 1 reference standard
(ERCP).
No - if the study had
more than 1 reference
standard.
Unclear - if the study was
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not clear about the refer-
ence standard used
4. Were all participants
included in the analy-
sis?
Answer:
Yes - if all participants
were included in the
analysis.
No - if more than 1
participant was excluded
from the analysis nomat-
ter the reason
Unclear - if it is not clear
about the exclusions of
participants from the
analysis
Risk of bias 1. Could the selection
of participants have in-
troduced bias?
Answer:
High - if participants
were enrolled retrospec-
tively, if the study did
not report the causes of
exclusions, and if other
imaging tests were used
before the index test or
reference standard
Low - if the studywas in a
consecutive or a random
selection of participants,
if participants were en-
rolled prospectively, and
if the study described ex-
clusions
Unclear - the study was
not clear about the de-
sign, if the exclusions
were not reported, and
there was no informa-
tion about if participants
were submitted or not to
other imaging tests
1. Could the conduct
or interpretation of the
combination of MRCP
and MRI have intro-
duced bias?
Answer:
High - the study re-
ported that results of the
combination of MRCP
and MRI were inter-
preted with the results of
reference standard
Low - the study reported
that results of combina-
tion of MRCP and MRI
were interpreted without
knowledge of the results
of reference standard and
there was a threshold to
consider a bile duct dila-
tion
Unclear - the study re-
ported no information
about blinding of the
results of the reference
standard and the com-
bination of MRCP and
MRI
1. Could the refer-
ence standard, its con-
duct, or its interpre-
tation have introduced
bias?
Answer:
High - the results of ref-
erence standard were in-
terpreted with the results
of the index test, and
when the study used a
reference standard that
did not classify the tar-
get condition correctly,
and the pool of refer-
ence standards was not
used for the correct tar-
get condition
Low - the results of
the reference standard
were interpreted with-
out knowledge of the re-
sults of the index test,
and ERCP alone or in
combination with other
tests classified and used
the target condition cor-
rectly
Unclear - the study
was not clear about the
1. Could the partici-
pant flow have intro-
duced bias?
Answer:
High - the study used
more than 1 reference
standard and the time
between the index test
and reference standard
was not clear
Low - the study used
only 1 reference standard
and all participants were
included in the analysis
Unclear - the study did
not report if all partic-
ipants received the ref-
erence standard, if the
study did not report the
interval between the ref-
erence standard and the
index test
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blinding with the results
of the reference standard
and the index test
Concerns about appli-
cability
1. Are there concerns
that the included par-
ticipants do not match
the review question?
Answer:
High - if participants
were enrolled for an in-
vestigation other than
for suspicion of bile duct
stenosis
Low - if participantswere
enrolled for investiga-
tion of suspicion of bile
duct stenosis
Unclear - if the study did
not report why the par-
ticipantswere enrolled in
the study
1. Are there concerns
that the combination
of MRCP and MRI,
its conduct, or its in-
terpretation differ from
the review question?
Answer:
High - if the study
did not report how the
combination of MRCP
andMRI was technically
conducted and which
magnetic field strength
was used
Low - if the combination
of MRCP and MRI re-
sults classified the target
condition appropriately,
if the study reported how
the
combination of MRCP
andMRI was technically
conducted and if field
strengths of 1.5 T or 3.0
T were used
Unclear - insufficient
data about the combina-
tion of MRCP and MRI
were reported
1. Are there concerns
that the target condi-
tion as defined by the
reference standard does
not match the review
question?
Answer:
High - if there was
no information how the
reference standard or a
pool of reference stan-
dards defined the bile
duct stenosis and bile
duct dilatation
Low - if the study re-
ported how the reference
standard or a pool of ref-
erence standards defined
the bile duct stenosis and
bile duct dilation
Unclear - the study did
not report sufficient data
on how the reference
standard or a pool of ref-
erence standards defined
the target condition
-
Footnotes:
• The reference standard for detection of presence and site of stenosis could only be ERCP or a combination of reference
standards; however, ERCP should always be part of this combination.
• The reference standard to differentiate benign from malignant stenosis will be a combination of tests as clinical follow-up,
surgical exploration, and histopathology.
• Studies with more than one objective may have more than one reference standard.
ERCP: endoscopic retrograde cholangiopancreatography; MRCP: magnetic resonance cholangiopancreatography; MRI: magnetic
resonance imaging; PTC: percutaneous transhepatic cholangiography
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